Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
By SquaredTown on December 9, 2025
LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with relapsed/refractory Multiple Myeloma (RRMM): Results of MajesTEC-3 ORLANDO, Fla., Dec. 9,...